ArticleMarine drugs2011
Heterofucans from the brown seaweed Canistrocarpus cervicornis with anticoagulant and antioxidant activities.
Article in Marine drugs, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 133 citations in OpenAlex.
- Pharmacological Properties and Phytochemical Profile ofMarine drugs · 2026Review
- Chemical Characterization and Bio-Screening of Neuroprotective Potential of Brazilian Brown SeaweedAntioxidants (Basel, Switzerland) · 2025Article
- Green fabrication of ZnO nanoparticles via spirulina platensis and its efficiency against biofilm forming pathogens.Microbial cell factories · 2024Article
- Review
- In Vitro Study of the Therapeutic Potential of Brown Crude Fucoidans in Osteoarthritis Treatment.International journal of molecular sciences · 2022Article
- Antioxidant Activity of Fucoidan Modified with Gallic Acid Using the Redox Method.Marine drugs · 2022Article
- Sulfated Galactofucans: An Outstanding Class of Fucoidans with Promising Bioactivities.Marine drugs · 2022Review
- Comparison of Antioxidant and Anticancer Properties of Soft Coral-Derived Sinularin and Dihydrosinularin.Molecules (Basel, Switzerland) · 2021Article
- Preparation of NewMolecules (Basel, Switzerland) · 2021Article
- On the Health Benefits vs. Risks of Seaweeds and Their Constituents: The Curious Case of the Polymer Paradigm.Marine drugs · 2021Article
- Fucoidan Characterization: Determination of Purity and Physicochemical and Chemical Properties.Marine drugs · 2020Review
- A Comprehensive and Comparative Analysis of the Fucoidan Compositional Data Across the Phaeophyceae.Frontiers in plant science · 2020Review
- Natural products against cancer: Review on phytochemicals from marine sources in preventing cancer.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2019Review
- Antioxidant Fucoidans Obtained from Tropical Seaweed Protect Pre-Osteoblastic Cells from Hydrogen Peroxide-Induced Damage.Marine drugs · 2019Article
- Anticoagulant Activity of Sulfated Ulvan Isolated from the Green MacroalgaMarine drugs · 2019Article
- 2-Allylphenol Reduces IL-1Oxidative medicine and cellular longevity · 2019Article
- Molecular networking prospection and characterization of terpenoids and CRSC advances · 2018Article
- Commercial Fucoidans fromMarine drugs · 2018Article
- Marine Diterpenes: Molecular Modeling of Thrombin Inhibitors with Potential Biotechnological Application as an Antithrombotic.Marine drugs · 2017Article
- Green Synthesis of Magnetite (Fe3O4) Nanoparticles Using Seaweed (Kappaphycus alvarezii) Extract.Nanoscale research letters · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Fucan is a term used to denominate a family of sulfated polysaccharides rich in sulfated l-fucose. We extracted six fucans from Canistrocarpus cervicornis by proteolytic digestion followed by sequential acetone precipitation. These heterofucans are composed mainly of fucose, glucuronic acid, galactose and sulfate. No polysaccharide was capable of prolonging prothrombin time (PT) at the concentration assayed. However, all polysaccharides prolonged activated partial thromboplastin time (aPTT). Four sulfated polysaccharides (CC-0.3/CC-0.5/CC-0.7/CC-1.0) doubled aPTT with only 0.1 mg/mL of plasma, only 1.25-fold less than Clexane, a commercial low molecular weight heparin. Heterofucans exhibited total antioxidant capacity, low hydroxyl radical scavenging activity, good superoxide radical scavenging efficiency (except CC-1.0), and excellent ferrous chelating ability (except CC-0.3). These results clearly indicate the beneficial effect of C. cervicornis polysaccharides as anticoagulants and antioxidants. Further purification steps and additional studies on structural features as well as in vivo experiments are needed to test the viability of their use as therapeutic agents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.